09/27/23 4:05 PMNasdaq : DCTH low floatDelcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, in the form of a total of 86,000 shares of the Company's common stock, outside of the Company's Omnibus 2020 Equity Incentive Plan as amended,...RHEA-AIvery positive
09/11/23 8:00 AMNasdaq : DCTH low floatA Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual MeetingDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral presentation by independent...RHEA-AIneutral
09/05/23 4:00 PMNasdaq : DCTH conferenceslow floatDelcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25 th Annual Global Investor Conference. Delcath CEO, Gerard Michel will present on September 13 at 11:00 AM ET. The Company's proprietary products, HEPZATO...RHEA-AIneutral
09/01/23 2:07 PMNasdaq : DCTH fda approvallow floatDelcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 million through the exercise of all the Tranche A warrants issued as part the previously announced March 29, 2023 Private Investment in Public...RHEA-AIneutral
08/14/23 9:10 PMNasdaq : DCTH fda approvallow floatDelcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal MelanomaDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the...RHEA-AIneutral
08/09/23 5:33 PMNasdaq : DCTH earningslow floatDelcath Systems Reports Second Quarter 2023 Results and Provides Business UpdateHas continued to communicate with the United States Food and Drug Administration as the agency continues its review of the HEPZATO KIT™ New Drug Application resubmission with an anticipated PDUFA date of August 14, 2023; Received stockholders approval for the potential issuance in excess of 19.99% of Delcath's outstanding common stock upon the...RHEA-AIneutral
08/03/23 8:30 AMNasdaq : DCTH conferencesearningslow floatDelcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following WeekDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it plans to report the Company's 2 Q23 earnings and issue its Form 10- Q the week of August 7, 2023. Subsequently, shortly after the FDA's decision on its HEPZATO™ KIT's new drug...RHEA-AIneutral
06/21/23 4:10 PMNasdaq : DCTH low floatDelcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment for two...RHEA-AIvery positive
06/20/23 8:30 AMNasdaq : DCTH managementlow floatDelcath Systems Appoints Vojislav Vukovic as Chief Medical OfficerDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Vojislav "Vojo" Vukovic as its new Chief Medical Officer. Vukovic earned his MD from the University of Sarajevo, a MSc in Radiation Biology and a PhD in...RHEA-AIneutral
06/07/23 4:10 PMNasdaq : DCTH low floatDelcath Systems Announces Sandra Pennell as Senior Vice President of FinanceDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance. Pennell joins the Company with over twenty-years of experience in a variety of...RHEA-AIneutral